Abstract: A method for treating acrolein reactor wastewater, comprising the steps of: S1. mixing acrolein reactor wastewater and a carbonate aqueous solution to obtain a mixed solution, wherein the acrolein reactor wastewater has a pH value of less than 2 and contains 500 ppm to 3,000 ppm of acrolein, 50 ppm to 800 ppm of allyl alcohol, 40,000 ppm to 100,000 ppm of acrylic acid, 10,000 ppm to 30,000 ppm of formaldehyde, 3,000 ppm to 10,000 ppm of acetic acid and 3,000 ppm to 8,000 ppm of maleic acid; and the mixed solution has a pH value of 4 to 6, a COD concentration ranging from 7,500 ppm to 30,000 ppm, and a formaldehyde concentration ranging from 800 ppm to 4,000 ppm; S2. conveying the mixed solution obtained in step S1 to an anaerobic reactor (4) for biochemical treatment; and S3. conveying the solution treated in step S2 to an aerobic biochemical tank (5) for treatment; and reflowing at least one part of the solution treated in step S2 and/or S3 to step S2.

Abstract: A method for treating acrolein reactor wastewater, comprising the steps of: S1. mixing acrolein reactor wastewater and a carbonate aqueous solution to obtain a mixed solution, wherein the acrolein reactor wastewater has a pH value of less than 2 and contains 500 ppm to 3,000 ppm of acrolein, 50 ppm to 800 ppm of allyl alcohol, 40,000 ppm to 100,000 ppm of acrylic acid, 10,000 ppm to 30,000 ppm of formaldehyde, 3,000 ppm to 10,000 ppm of acetic acid and 3,000 ppm to 8,000 ppm of maleic acid; and the mixed solution has a pH value of 4 to 6, a COD concentration ranging from 7,500 ppm to 30,000 ppm, and a formaldehyde concentration ranging from 800 ppm to 4,000 ppm; S2. conveying the mixed solution obtained in step S1 to an anaerobic reactor (4) for biochemical treatment; and S3. conveying the solution treated in step S2 to an aerobic biochemical tank (5) for treatment; and reflowing at least one part of the solution treated in step S2 and/or S3 to step S2.

Abstract: The present invention provides a process for purifying methionine. A methionine product having a purity of up to 99% or higher is obtained by separating methionine from a salt by-product through a process comprising adsorption and desorption using a macroporous adsorption resin, where the methionine content in the salt by-product is ?0.03%. The yield of methionine extracted with the resin is up to 98% or higher. By using the process of the present invention, the existing production process is simplified, the quality of the methionine product is improved, and the production costs for methionine are reduced.

Abstract: The present invention provides a process for purifying methionine. A methionine product having a purity of up to 99% or higher is obtained by separating methionine from a salt by-product through a process comprising adsorption and desorption using a macroporous adsorption resin, where the methionine content in the salt by-product is 0.03%. The yield of methionine extracted with the resin is up to 98% or higher. By using the process of the present invention, the existing production process is simplified, the quality of the methionine product is improved, and the production costs for methionine are reduced.

Abstract: The present invention provides a process for purifying methionine. A methionine product having a purity of up to 99% or higher is obtained by separating methionine from a salt by-product through a process comprising adsorption and desorption using a macroporous adsorption resin, where the methionine content in the salt by-product is ?0.03%. The yield of methionine extracted with the resin is up to 98% or higher. By using the process of the present invention, the existing production process is simplified, the quality of the methionine product is improved, and the production costs for methionine are reduced.

Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.

Abstract: The present invention provides a process for purifying methionine. A methionine product having a purity of up to 99% or higher is obtained by separating methionine from a salt by-product through a process comprising adsorption and desorption using a macroporous adsorption resin, where the methionine content in the salt by-product is ?0.03%. The yield of methionine extracted with the resin is up to 98% or higher. By using the process of the present invention, the existing production process is simplified, the quality of the methionine product is improved, and the production costs for methionine are reduced.

Abstract: The present invention relates to a method for preparation of the trisaccharide 6?-O-sialyllactose (formula (I)) or salts thereof as well as intermediates in the synthesis and for the use of 6?-O-sialyllactose salts in pharmaceutical or nutritional compositions.

Abstract: The invention relates to a method for the synthesis of compounds of general formula (1A) and salts thereof wherein one of the R groups is an ?-sialyl moiety and the other is H, X1 represents a carbohydrate linker, A is a D-glucopyranosyl unit optionally substituted with fucosyl, R1 is a protecting group that is removable by hydrogenolysis, the integer m is 0 or 1, by a transsialidation reaction.

Abstract: The present invention relates to an improved synthesis of a trisaccharide of the formula (1), novel intermediates used in the synthesis and the preparation of the intermediates.

Abstract: The present invention relates to a method for preparation of the tetrasaccharide lacto-N-neotetraose (LNnt, formula (I)) especially in large scale, as well as intermediates in the synthesis, a new crystal form (polymorph) of LNnt, and the use thereof in pharmaceutical or nutritional compositions.

Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.

Abstract: The present invention relates to an improved synthesis of a trisaccharide of the formula, novel intermediates used in the synthesis and the preparation of the intermediates.

Abstract: The present application discloses a method for the crystallization of fucose, characterized in that the crystallization is carried out from a mixture comprising fucose and at least one 6-deoxy sugar selected from 6-deoxy-talose and 6-deoxy-gulose. In one embodiment, the mixture comprises fucose and 6-deoxy-talose.

Abstract: The present invention relates to novel polymorphs of the trisaccharide 2?-O-fucosyllactose (2-FL) of formula (1), methods for producing said polymorphs and their use in pharmaceutical or nutritional compositions.

Abstract: The invention relates to providing isolactosamine (Gal?1-3GlcNH2, formula 1) and salts thereof in the form of either anomer or mixture thereof, as well as hydrates or solvates of the free base and salts thereof. The synthesis of isolactosamine and its use in the synthesis of lacto-N-biose containing oligosaccharides are also disclosed.

Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.

Abstract: A method that can be used to make a precursor of L-fucose from D-glucose that includes the steps of a) making a compound of formula (1) from D-glucose, formula (1) wherein R1 is acyloxy, and Q is a group (a), (b), (c) or (d), formula (a), (b), (c) or (d) or wherein R1 is OH, and Q is a group (e), (f) or (g); formula (e), (f) or (g) wherein R2 is acyloxy and R3 is a sulphonyl leaving group; and b) producing 6-deoxy-L-talose from the compound of formula (1) formed in step a), wherein the moiety is a highly lipophilic protecting group; compounds according to formula (1), and use of a compound according to formula (1) are provided.

Abstract: A process for converting D-glucose into L-fucose, where a first aspect of the disclosure relates to a method of making a compound of formula (1) wherein R is independently H, alkyl or phenyl or, preferably, wherein the two germinal R groups together with the carbon atom to which they are attached form a C3-s cycloalkylidene group, including the step of treating a compound of formula (2) wherein R is defined above and R1 is a sulphonate leaving group, with a reducing complex metal hydride and, preferably, a base to form the compound of formula (1); a compound of formula (13).

Abstract: Method for producing L-fucose includes in a first aspect, a method for the preparation of L-fucose, wherein L-fucose precursors are produced from pectin and L-fucose is produced from the L-fucose precursors; in a second aspect, a method for the preparation of L-fucose from D-galacturonic acid or a salt thereof, wherein L-fucose precursors are produced from D-galacturonic acid of a salt thereof, and L-fucose is produced from the L-fucose precursors; and an L-fucose precursor as shown in Formula A, wherein R is a linear or branched chain saturated hydrocarbon group with 1-6 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-hexyl, etc., preferably a methyl group.